First real-world experience with inclisiran in Spain: Efficacy, safety, and prescription patterns in clinical practice.
Inclisiran's twice-yearly dosing and strong LDL-cholesterol reduction offer a practical option for patients struggling with statin therapy.
Low-density lipoprotein cholesterol (LDL-C) is a key causal factor in atherosclerotic cardiovascular disease, and inclisiran—a small interfering RNA inhibiting hepatic PCSK9 synthesis—has demonstrated marked LDL-C reductions in clinical trials. In this first real-world Spanish cohort, inclisiran showed a favorable safety profile and twice-yearly administration that supports its practical integration into clinical lipid-lowering practice, particularly for patients with statin intolerance or adherence difficulties.
What the study was
- Study design
- Not specified
- Population
- Cancer/disease patients
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Why it surfaced
Matched topic(s): Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk. Study design: Not specified. Score 6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.